1223446-32-9

Upstream product

• 141-91-3 cis-2,6-dimethylmorpholine 
• 914935-66-3 [2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-3,4-difluorophenyl]methanol 
• 914935-65-2 2-((2R,6S)-2,6-dimethylmorpholin-4-yl)-3,4-difluorobenzoic acid 
• 914935-67-4 (2R,6S)-4-[6-({[tert-butyl(diphenyl)silyl]oxy}methyl)-2,3-difluorophenyl]-2,6-dimethylmorpholine 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 
• 1223445-92-8 1-(5-((tert-butyldiphenylsilyloxy)methyl)-4-((2R,6S)-2,6-dimethylmorpholino)-2,3-difluorophenyl)-2,2,2-trifluoroethanone 

Relevant academic research and scientific papers

Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: Sar and in vivo characterization

The compounds described herein with a spirocyclic architecture fused to a benzisoxazole ring represent a new class of antibacterial agents that operate by inhibition of DNA gyrase as corroborated in an enzyme assay and by the inhibition of precursor thymi

FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

The present invention relates to compounds of Formula (I); to pharmaceutical1y acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation